1/x Some thoughts on Coursera $COUR vs Udemy $UDMY. Udemy currently trades at an enterprise value of $1,723mm (2.75x EV/FY'22 Sales) vs Coursera's of $1,048mm (2.05x EV/FY'22 Sales). Both platforms offer free and paid educational courses online. DM for full models on both. 2/x Both have a consumer and enterprise segment offering. Consumer offerings are fixed or recurring subscription payments. Enterprise offerings for both are are subscriptions based on volume consumed or number of seats.

1/25 A summary of Roblox's ( $RBLX ) core business and some thoughts on bull/bear cases. Roblox is a 3-d online multiplayer game platform and creation system. Users create their own virtual customizable avatar and interact with others while playing user-created “experiences”. 2/25
These are essentially mini-games built using Roblox’s dev tools. The game is free to play and derives almost all its revenue through the sale of Robux, a virtual currency used to buy items within the game as well as their premium membership. Robux are purchased by users

1/ $BGXX aims to be the premier federally-authorized provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies. It went public through a direct listing with 157mm shares issued and 200mm authorized. There is no lock-up for insider selling 2/ The company reported a net loss for the 9 months ended September 30 2021 of $1.57mm and $3mm with no revenue. They list two officers, the CEO, and CFO with no full-time employees. None of the board members seem to have any prior experience in the cannabis industry.

1/ $RGC uses Traditional Chinese Medicine for ADHD and ASD. The company has no product/revenue and paid its IPO proceeds to the CEO's father for his "research":tinyurl.com/4pe8va8k(not peer reviewed, needless to say). 1.5M float, 460M valuation 2/ The CEO owns 80% of all shares and there are 100M shares authorized looming over the publics' head ready to extract value. The CEO's father("TCM practitioner) has "treated" Alzheimer’s disease, depression, arthritis, diabetes, SARS and COVID-19 with "promising results"

1/ $SKYX SQL technologies Corp set for trading Feb 11 is the most ridiculous IPO this year(973M value on the conversion of preferred shares). The company spent years manufacturing and selling ceiling fans and lighting fixtures under GE's brand after paying them $12M for licensing 2/ This low-margin business earned heavy net losses every year(2014:7.3M, 2015:27M, 2016:98M(yes, really:tinyurl.com/2p8d6awz), 2017:26.7M, 2018:9M+, 2019: 16.9M, 2020: 9.2M) towards an accumulated deficit of $72.2M as of September 30th 2021.

1/ $AMLX Upcoming IPO(Feb 7th) Amylyx pharmaceuticals has developed a drug(AMX0035) for the treatment of ALS. They believe it is the first to both slow decline and lengthen the life of ALS patients. We believe the drug is inert and will fail its upcoming Phase 3 Phoenix trial. 2/ The company has made the extraordinary claim that they believe data from the PHOENIX trial will not be required for the FDA to make a determination on the approval of AMX0035 for the treatment of ALS based on their discussions with the FDA.